Comparative Pharmacology
Head-to-head clinical analysis: CARDIOTEC versus DRAXIMAGE MDP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOTEC versus DRAXIMAGE MDP 25.
CARDIOTEC vs DRAXIMAGE MDP-25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARDIOTEC is a technetium-99m labeled tracer that binds to viable myocardial cells. Its uptake is dependent on mitochondrial membrane potential and reflects myocardial perfusion and viability. The exact mechanism involves passive diffusion across cell membranes and retention within mitochondria via interaction with the mitochondrial complex I (NADH dehydrogenase).
Technetium-99m methylene diphosphonate (MDP) is a bone-seeking radiopharmaceutical. After intravenous injection, it adsorbs onto hydroxyapatite crystals in bone, with increased uptake in areas of high metabolic activity or blood flow, such as tumors or fractures. The technetium-99m emits gamma rays which are detected by a gamma camera for imaging.
220-260 MBq (6-7 mCi) intravenously as a single dose for planar or SPECT imaging.
555–925 MBq (15–25 mCi) intravenously for bone scintigraphy; imaging performed 2–4 hours post-injection
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; clinically, steady-state achieved in 24-32 hours
Terminal elimination half-life is approximately 6-8 hours for the primary complex; minor radiochemical impurities may have longer half-lives
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Primarily renal (urinary excretion of 60-70% as unchanged drug within 24 hours, with 5-10% biliary excretion)
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical